In fact, although almost 95% of PV and 50–60% of ET and PMF patients harbor JAK2 mutations [5], clinical experience suggests that targeting JAK2 may not be sufficient to eliminate malignant mutated cells [10]. The gene discussed is JAK2; the disease is acquired polycythemia vera.